Prolonged response to early docetaxel in a patient with biochemical relapse after primary therapy for prostate cancer and incomplete response to androgen suppression therapy - Abstract

Knight Cancer Institute, Oregon Health and Science University, Mail Code L586, 3181 SW Sam Jackson Park Road, Portland, OR 97239 U.S.A.

 

Sensitivity to androgen suppression therapy (AST) is a key determinant of survival in patients with non-localized prostate cancer. While an incomplete response to AST is associated with poor survival, additional therapy is typically withheld until obvious cancer progression. It is not known if the application of additional therapy earlier can have a favorable impact on long-term outcomes. We present the case of a patient with biochemically relapsed prostate cancer treated with early docetaxel after initial incomplete response to AST who now has a prolonged response to therapy.

Written by:
Barnett CM, Flamiatos JF, Beer TM.   Are you the author?

Reference: Anticancer Res. 2011 Mar;31(3):973-4.

PubMed Abstract
PMID: 21498723

UroToday.com Prostate Cancer Section

 

 

email news signup